Bloomberg News and Videos — Page 125

On this episode of Stock Movers: - Forte Bioscience (FBRX) is soaring as Argenx SE agreed to buy Forte Biosciences Inc. for about $2.2 billion in cash to expand its portfolio of immunology medicines. - Astrazeneca (AZN) shares rose after it reported higher-than-expected profit, buoyed by blockbuster cancer medicines, with earnings per share rising 21% to $2.63 last quarter. - Paramount Skydance (PSKY) shares are reacting to news that it paused its blockbuster deal for Warner Bros.

A pause in attacks for a third straight day between the US and Iran helped to push down oil prices and boost global stock and bond markets following two weeks of clashes. Tyler Kendall reports on Bloomberg Television.

Nvidia is in talks with OpenAI guarantee $250 billion in financing to help it open a data center in Ohio. OpenAI is already a customer of Nvidia. These deals have raised concerns about circular financing and skewed incentives. Bloomberg's Ed Ludlow reports.

Savita Subramanian, head of US equity and quantitative strategy at BofA Securities, says it seems that the idea that mega-cap tech stocks will continue to lead markets to new highs "is no longer the case."

Lisa Shalett, CIO at Morgan Stanley Wealth Management, sees a changing market narrative around capex spending by mega-cap tech companies ahead of earnings this week Microsoft, Apple, and others.

Nvidia is in discussions to provide a financing guarantee to help OpenAI lease a $500 billion, 10-gigawatt hub that SoftBank Group is overseeing in Ohio, people familiar with the matter said. Peter Elstrom reports on Bloomberg Television.

Plurimi Wealth CIO Patrick Armstrong discusses market moves as oil prices dropped after the US paused almost two weeks of daily strikes against Iran. "Even if we do get a relatively open Strait of Hormuz, it is going to be a restocking phase that'll support oil prices," Armstrong tells Bloomberg Television. He adds that oil around $90 a barrel is "a headwind for growth but not terribly so," but should prices go higher, it puts central banks in a "very difficult position."

AstraZeneca Chief Financial Officer Aradhana Sarin says the company is "very much on track" to reach its $80 billion sales target by 2030. "From a pharma standpoint, we are probably one of the most diversified from a product and pipeline, as well as probably the most diversified geographically," Sarin says. She speaks on Bloomberg Television as the company reported higher-than-expected profit, buoyed by blockbuster cancer medicines.

Anna Edwards, Guy Johnson and Skylar Montgomery Koning break down today's key themes for analysts and investors on "Bloomberg: The Opening Trade."

AI is changing the game for regional consulting amid geopolitical uncertainty and rising competition between major economies. Tamer Charife, Technology and Transformation Growth Leader at Deloitte Middle East spoke to Bloomberg's Abeer Abu Omar on Horizons Middle East and Africa on the data center investments & AI push in the region.